2197. Ceftriaxone Monotherapy vs. Ceftriaxone Plus Azithromycin for the Treatment of Community-Acquired Pneumonia in Hospitalized Non-ICU Patients

摘要

BackgroundCommunity-acquired pneumonia (CAP) is the leading infectious cause of death and severe sepsis in the United States and the fifth leading cause of death overall worldwide. Current United States guidelines for the treatment of CAP recommend empiric antibiotic therapy that covers both standard organisms as well as atypical organisms. Ceftriaxone (CTX) in combination with azithromycin (AZH) is one of the most common regimens used for the treatment of CAP; however, there are studies that show β-lactam monotherapy is as effective as a β-lactam in combination with AZH for the empiric treatment of CAP. The purpose of this study was to compare the rates of treatment failure between CTX monotherapy and CTX in combination with AZH in non-intensive care unit (ICU) inpatients.